We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $385.74, moving +1.01% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.59%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq appreciated by 0.44%.
The stock of drugmaker has fallen by 2.6% in the past month, lagging the Medical sector's loss of 0.94% and the S&P 500's gain of 2.72%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of $4.56, marking a 4.11% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $3.04 billion, reflecting a 9.8% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.98 per share and revenue of $11.98 billion, indicating changes of +4180.95% and +8.75%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 21.24. This denotes a premium relative to the industry average Forward P/E of 18.92.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 98, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $385.74, moving +1.01% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.59%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq appreciated by 0.44%.
The stock of drugmaker has fallen by 2.6% in the past month, lagging the Medical sector's loss of 0.94% and the S&P 500's gain of 2.72%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of $4.56, marking a 4.11% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $3.04 billion, reflecting a 9.8% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.98 per share and revenue of $11.98 billion, indicating changes of +4180.95% and +8.75%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 21.24. This denotes a premium relative to the industry average Forward P/E of 18.92.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 98, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.